Promex hires David Fromm as VP of engineering

Promex Industries, a Silicon Valley-based provider of advanced microelectronic component assembly and design services for the medtech and biotech industries, has hired David Fromm as vice president of engineering.

With a long and successful career in medical technology, Fromm will help lead Promex in the development of new go-to-market core technologies as capabilities and services are further expanded to medtech and biotechnology customers.

With more than 15 years’ experience in hardware, systems, and product design, Fromm will contribute his expertise within medical technologies, providing a link between customer needs and technical implementation required for commercial realisation with new and updated Promex processes.

Promex CEO Dick Otte said: “We are confident that Promex’s position as an industry leader will benefit significantly from the technical expertise, industry contacts and vast product development experience David will bring to bear. He also brings a fresh customer perspective to our current operations as he develops robust go-to-market strategies for new products. Moving forward, we are better positioned to accelerate the development and provision of technology that meets emerging compliance requirements, addresses evolving industry necessities and allows for future-generation use cases.”

Before joining Promex, Fromm served as director of instrument research for Cepheid, a molecular diagnostics company for more than seven years. Prior to that, he served in multiple roles developing complex instrumentation systems. He holds a Ph.D. in Physical Chemistry from Stanford University and a B.A. in Biochemistry from the University of Colorado- Boulder. Fromm is named on six patents in molecular diagnostics, advanced thermal control, and atomic force microscopy instrumentation.

Fromm added: “Working with a customer focus is a refreshing new element in my new role. I will be able to tackle obstacles and barriers bridging development to early production and through full manufacturing scale-up, which will improve customer engagement, customer experience, and time to market. We have an opportunity to build technology that transforms the biomedical space. I’m pleased to contribute to a team of world-leading experts in bringing critical, full-scale solutions from concept to reality.”